- Home
- MLYS vs NDMO Comparison
MLYS vs NDMO Comparison
Compare MLYS & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- NDMO
- Stock Information
- Founded
- MLYS 2019
- NDMO 2019
- Country
- MLYS United States
- NDMO United States
- Employees
- MLYS N/A
- NDMO N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- MLYS Health Care
- NDMO Finance
- Exchange
- MLYS Nasdaq
- NDMO Nasdaq
- Market Cap
- MLYS 634.6M
- NDMO 596.2M
- IPO Year
- MLYS 2023
- NDMO N/A
- Fundamental
- Price
- MLYS $9.24
- NDMO $10.37
- Analyst Decision
- MLYS Strong Buy
- NDMO
- Analyst Count
- MLYS 2
- NDMO 0
- Target Price
- MLYS $30.00
- NDMO N/A
- AVG Volume (30 Days)
- MLYS 266.6K
- NDMO 218.6K
- Earning Date
- MLYS 11-11-2024
- NDMO 01-01-0001
- Dividend Yield
- MLYS N/A
- NDMO 6.75%
- EPS Growth
- MLYS N/A
- NDMO N/A
- EPS
- MLYS N/A
- NDMO N/A
- Revenue
- MLYS N/A
- NDMO N/A
- Revenue This Year
- MLYS N/A
- NDMO N/A
- Revenue Next Year
- MLYS N/A
- NDMO N/A
- P/E Ratio
- MLYS N/A
- NDMO N/A
- Revenue Growth
- MLYS N/A
- NDMO N/A
- 52 Week Low
- MLYS $8.28
- NDMO $8.99
- 52 Week High
- MLYS $16.91
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- MLYS 32.12
- NDMO 57.84
- Support Level
- MLYS $8.60
- NDMO $10.08
- Resistance Level
- MLYS $9.97
- NDMO $10.25
- Average True Range (ATR)
- MLYS 0.88
- NDMO 0.11
- MACD
- MLYS -0.31
- NDMO 0.05
- Stochastic Oscillator
- MLYS 13.25
- NDMO 100.00
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.